Education
About Us
Working with TipRanks
Follow Us
SMS Pharmaceuticals Limited (IN:SMSPHARMA)
:SMSPHARMA
SMSPHARMA Stock Chart & Stats
₹325.40
-₹5.32(-2.16%)
At close: 4:00 PM EST
₹325.40
-₹5.32(-2.16%)
Day’s Range― - ―
52-Week Range₹175.00 - ₹433.80
Previous CloseN/A
Volume71.57K
Average Volume (3M)105.50K
Market Cap
₹34.66B
Enterprise Value₹36.78B
Total Cash (Recent Filing)₹1.02B
Total Debt (Recent Filing)₹3.24B
Price to Earnings (P/E)30.0
Beta1.49
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)2.51
Shares Outstanding93,652,030
10 Day Avg. Volume15,241
30 Day Avg. Volume105,503
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.91
Price to Sales (P/S)2.38
P/FCF Ratio-31.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSteady revenue expansion from 2020–2025 indicates durable end-market demand for APIs and stronger customer adoption. Over 2–6 months this supports capacity utilization, predictable top-line cash flows, and the ability to invest in process improvements or regulatory compliance without relying on short-term market moves.
Healthy Operating MarginsConsistently healthy EBIT/EBITDA margins suggest manufacturing efficiency and pricing power in key API products. Sustained operating profitability provides buffer against input cost swings, funds reinvestment and R&D, and supports long-term cash generation even if revenue growth moderates.
Solid Equity-backed Balance SheetA relatively strong equity base with moderate leverage gives financial flexibility to fund capex, regulatory compliance and capacity additions typical in pharma manufacturing. This structural stability lowers insolvency risk and preserves strategic optionality over the medium term.
Bears Say
Volatile Free Cash FlowSignificant FCF volatility and intermittent negative free cash flow constrain the company's ability to self-fund investments, deleverage or smooth dividends. Over months to a few quarters, this raises funding risk for regulatory capex and increases reliance on external financing when working capital or capex needs spike.
2023 Net Income WeaknessA pronounced net income decline and negative ROE in 2023 point to earnings-quality issues—cost pressures, one-offs, or pricing erosion. Without corrective measures, such episodes can persist and impair retained earnings, hamper reinvestment capacity and weaken long-term profitability metrics.
Rising Debt Levels To MonitorAn upward trend in leverage increases interest and refinancing risk, especially given cash flow variability. For a capital- and compliance-intensive API manufacturer, higher debt can limit investment flexibility and amplify stress during demand slowdowns or raw material cost shocks over the medium term.
SMS Pharmaceuticals Limited News
SMSPHARMA FAQ
What was SMS Pharmaceuticals Limited’s price range in the past 12 months?
SMS Pharmaceuticals Limited lowest stock price was ₹175.00 and its highest was ₹433.80 in the past 12 months.
What is SMS Pharmaceuticals Limited’s market cap?
SMS Pharmaceuticals Limited’s market cap is ₹34.66B.
When is SMS Pharmaceuticals Limited’s upcoming earnings report date?
SMS Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 80 days.
How were SMS Pharmaceuticals Limited’s earnings last quarter?
SMS Pharmaceuticals Limited released its earnings results on Feb 07, 2026. The company reported ₹2.506 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.506.
Is SMS Pharmaceuticals Limited overvalued?
According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Overvalued.
Does SMS Pharmaceuticals Limited pay dividends?
SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.13%. See more information on SMS Pharmaceuticals Limited dividends here
What is SMS Pharmaceuticals Limited’s EPS estimate?
SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Pharmaceuticals Limited have?
SMS Pharmaceuticals Limited has 93,652,030 shares outstanding.
What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?
SMS Pharmaceuticals Limited reported an EPS of ₹2.506 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.745%.
Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:SMSPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.
Technical Analysis
Bajaj Healthcare Ltd
―
Indoco Remedies Limited
―
Medi Assist Healthcare Services Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―